Curcumin & Turmeric Effectiveness Research Abstract For Professionals

Real-World Effectiveness of Curcumin & Turmeric for Joint and Inflammatory Symptoms: User-Reported Outcomes from a Cross-Sectional Customer Survey

June 2026

Key Findings

1. 94.5% of users who gave a definitive rating found DR.VEGAN^® Curcumin & Turmeric effective (n=55), with 40.0% rating it very effective and a combined negative rate of just 5.5%.
   
2. Joint pain was the dominant target and the dominant benefit: among the 49 users who experienced joint aches or pain before use, 81.6% reported relief — and relief from inflammation was reported by 69.2% of those affected.
   
3. Relief was concentrated in the most commonly affected joints: the knees (42.6% of all users), hips (27.9%), and hands or fingers (19.7%) — mirroring the baseline pain distribution.
   
4. Advocacy was strong: a Net Promoter Score of +50, a mean recommendation score of 8.6 out of 10, and 84.5% scoring 7 or above.
   
5. Onset was rapid for an anti-inflammatory supplement: 64.0% of those reporting a timeframe felt benefits within four weeks and 84.0% within eight weeks; the very-effective rating rose to 50.0% among users of two years or more.

Background

Curcumin, the principal active compound in turmeric, is among the most widely studied botanical anti-inflammatory agents, with a substantial body of evidence examining its role in joint health and the management of inflammatory symptoms. Joint pain, stiffness, and inflammation - frequently associated with osteoarthritis and other musculoskeletal conditions - are highly prevalent in midlife and older adults and have a marked impact on mobility and quality of life. DR.VEGAN^® Curcumin & Turmeric is a plant-based formulation designed to support joint comfort, mobility, and the management of inflammation. This abstract reports real-world, user-reported outcomes from a cross-sectional customer survey, including the clinical and symptom profile of users, overall effectiveness, symptom-level relief among prior sufferers, the anatomical distribution of benefit, time to benefit, and likelihood to recommend.

Methods

A cross-sectional customer feedback survey was administered to DR.VEGAN^® customers, yielding 61 analysable responses, of whom 95.1% were current users. Respondents reported age and gender; any clinical musculoskeletal diagnoses; the symptoms and joint-pain locations experienced before use; duration and consistency of use; overall effectiveness (four-point scale plus a ‘too early to tell’ option); the symptoms and body areas in which they felt a difference; time to first benefit; and likelihood to recommend on a 0–10 scale. Effectiveness percentages are reported among respondents who provided a definitive rating, excluding ‘too early to tell’. Symptom relief was calculated among the subset who had experienced each symptom before use. Individual-level data were analysed for all responses. As a modest sample (n=61) drawn from existing customers, results should be interpreted as real-world user feedback rather than as controlled trial evidence.

Results

Cohort profile

The cohort was predominantly female (82.0%) and older, with 93.4% aged 45 or over and 32.8% aged 65 or over - a demographic profile consistent with the populations most affected by joint and inflammatory complaints. Clinical diagnoses were common: 45.9% reported at least one musculoskeletal diagnosis, most frequently arthritis (24.6%) and osteoarthritis (18.0%). Baseline symptoms were dominated by joint aches or pain (80.3%), followed by tiredness and fatigue (50.8%), inflammation (42.6%), and muscle aches or pains (41.0%). Joint pain was most commonly experienced in the knees (57.4%), hips (45.9%), and hands or fingers (36.1%). Use was sustained and highly adherent: 55.8% had taken the product for one year or more, and 95.1% took it daily or most days.

Overall effectiveness

Of the 55 respondents who gave a definitive rating, 94.5% rated Curcumin & Turmeric effective — 40.0% very effective and 54.5% somewhat effective. Only 3.6% rated it not so effective and 1.8% not at all effective, giving a combined negative rate of 5.5%. See Figure 1.

Symptom relief among prior sufferers

To assess relief precisely, the relief rate was calculated among only those respondents who had experienced each symptom before use. On this basis, the product’s effect was clearly concentrated in its primary indication: 81.6% of the 49 prior joint-pain sufferers reported relief, and 69.2% of those with inflammation. Relief rates were more modest for secondary symptoms such as muscle aches (44.0%) and limited joint movement (18.2%), and minimal for non-musculoskeletal symptoms such as fatigue — a pattern consistent with curcumin’s recognised anti-inflammatory mechanism. Overall, 78.7% reported relief in at least one symptom. See Figure 2.

Duration-response relationship

Sustained use was associated with a stronger response. The very-effective rating rose with duration of use, reaching 50.0% among users of two years or more, versus 33.3% among those using it under one year, while the combined positive rate remained consistently high (92–96%) across all duration bands. This pattern is consistent with the cumulative anti-inflammatory effect of sustained curcumin supplementation. See Figure 3.

Onset and advocacy

Onset of benefit was relatively rapid for an anti-inflammatory supplement: of the 50 respondents reporting a timeframe, 64.0% felt benefits within four weeks and 84.0% within eight weeks. Advocacy was strong, with a mean recommendation score of 8.6 out of 10, 84.5% scoring 7 or above, and a Net Promoter Score of +50 (65.5% promoters against 15.5% detractors). See Figure 4.

Conclusions

In this real-world feedback survey of 61 predominantly older, female users — nearly half with a diagnosed musculoskeletal condition — DR.VEGAN^® Curcumin & Turmeric demonstrated a high user-reported effectiveness rate (94.5%) and targeted relief in its primary indication, with 81.6% of prior joint-pain sufferers and 69.2% of those with inflammation reporting improvement. The concentration of benefit in joint pain and inflammation, the anatomical alignment of relief with the most affected joints, and the comparatively limited effect on non-musculoskeletal symptoms together present a coherent picture consistent with curcumin’s established anti-inflammatory mechanism. Sustained use was associated with a higher very-effective rating, and onset was rapid for this supplement class. Advocacy was strong (NPS +50). The principal limitations are the modest sample size, the absence of a control group, reliance on self-reported outcomes, and a cohort weighted toward long-term users, which may bias the effectiveness estimate upward relative to a treatment-naive population. Prospective, controlled studies using validated joint-pain and inflammation instruments and defined follow-up intervals would allow these promising real-world signals to be confirmed.

Keywords: Curcumin, turmeric, joint health, inflammation, joint pain, osteoarthritis, anti-inflammatory, musculoskeletal, user-reported outcomes, net promoter score, plant-based supplement

Survey date: 2024–2025  |  Respondents: N = 61  |  Adherence: 95.1% daily or most days  |  Data type: Individual-level responses

Media enquiries: Please contact [email protected]   |   www.drvegan.com